In one study of people who had type 2 diabetes with early nephropathy and normal renal function, adding spironolactone to ACEI treatment was shown to be clinically useful and safe for people who showed aldosterone escape during ACEI treatment and who no longer showed maximal antiproteinuric effects of ACE inhibition [152, 153]. Here, ACE is linked to kidney disorder.